Project Details
Projekt
Deciphering resistance against targeted treatments (A03)
Subject Area
Hematology, Oncology
Term
since 2019
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 404521405
Patient tumor tissues from N²M², a trial using molecular defined treatments first-line with radiotherapy alone, are analyzed with single nuclei (sn) RNA sequencing next to comprehensive molecular analysis to understand resistance pathways and subclonal evolution under targeted therapies. Putative resistance pathways will be studied in vitro and in vivo. With a specific focus in understanding the role of senescent tumor cells promoting this targeted therapy resistance. In addition, molecular, metabolic and imaging biomarkers from two retrospective as well as one prospective study will be analyzed.
DFG Programme
Collaborative Research Centres
Applicant Institution
Ruprecht-Karls-Universität Heidelberg
Project Heads
Dr. Tobias Kessler; Professor Dr. Wolfgang Wick
